Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Herbal blend shows promise for quick cough relief in new trial

NCT ID NCT07420491

Symptom relief Sponsor: Dexa Medica Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether Reconyl, a mix of four Indonesian herbs, can safely ease acute cough better than a placebo. 144 adults with sudden cough took either Reconyl or a placebo three times daily for 7 days. Researchers measured changes in cough severity and quality of life, along with kidney and liver function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Reconyl (a blend of four Indonesian herbs: Vitex trifolia, ginger, Abrus precatorius, and Phaleria macrocarpa)
What this could lead to
If it works, this could provide a natural, side-effect-free option for relieving acute cough.
What could go wrong
This is a small, completed Phase 3 trial with only 144 participants. The herbal blend may not work better than a placebo, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

144 people

The number who actually took part.

Started

Jun 2025

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed informed consent from the subject or the subject's legally acceptable representatives (must obtained before any trial related activities) 2. Male or female subjects, aged 18-50 years at screening 3. Experience acute cough, defined as sudden onset dominant or main symptom of acute or worsened cough, with or without sputum, in the span of 72 hours, avoiding prescription and non-prescription cough-relieving medications (e.g. antitusives such as codeine-based cough supressants or dextromethorphan HBr, and mucolytics such as N-acetylsistein, Bromhexin and Ambroxol), within 24 hours before entering the study. 4. The condition of the patient does not have any illness other than acute cough that could possibly interfere with the study evaluation, such as chronic obstructive pulmonary disease (COPD), suspect GERD, rhinitis, asthma, tuberculosis (TB), and pneumonia. 5. Cooperative and able to fill out study material Exclusion Criteria: 1. Subject with febrile within 24 hours before screening, or has body temperature ≥ 38°C during screening visit 2. Personal/family history of allergy or hypersensitivity or contradiction to any component of the drugs 3. History or clinical evidence of immunosuppression according to investigator assessment, or currently under treatment with immunosuppressive agents 4. Participation in any other trial less than 90 days before 5. Pregnancy or lactation 6. History of drug or alcohol abuse within 12 months prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cough are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cough

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cough

Contacts and locations

Locations

  • Velia Medika Primary Care Clinic

    Jakarta, Jakarta Special Capital Region, 12430, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.